<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05629806</url>
  </required_header>
  <id_info>
    <org_study_id>KY20220314-02</org_study_id>
    <nct_id>NCT05629806</nct_id>
  </id_info>
  <brief_title>Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes</brief_title>
  <official_title>Effect of Acarbose and Fixed Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes Receiving Anti-diabetic Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monotherapy with DPP-IV inhibitors, SGLT-2 inhibitors or insulin secretagogues frequently&#xD;
      failed to maintain blood glucose in patients with type 2 diabtes. It was critical to&#xD;
      determine which was more suitable of acarbose versus metformin plus pioglitazone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2022</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose fluctuation</measure>
    <time_frame>week 24</time_frame>
    <description>change from baseline blood glucsoe fluctuation at end of study</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Blood Glucose Fluctuation</condition>
  <arm_group>
    <arm_group_label>Metformin plus pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Acarbose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin plus pioglitazone</intervention_name>
    <description>After the screening period, eligible subjects were admitted to two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. Then the subjects were titrated onto the alternative treatment of 50mg acarbose three times daily for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.</description>
    <arm_group_label>Acarbose</arm_group_label>
    <arm_group_label>Metformin plus pioglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <description>After the screening period, eligible subjects were admitted to 50mg acarbose three times daily for 12 weeks. Then the subjects were titrated onto the alternative treatment of two tablets of fixed mixture of metformin plus pioglitazone (15mg pioglitazone plus 500mg metformin) for 12 weeks. During this timeframe, all patients were instructed to monitor their blood glucose fluctuations with a FreeStyle Libre Pro Sensor (FGM system) before and after the study and the time point of drug replacement.</description>
    <arm_group_label>Acarbose</arm_group_label>
    <arm_group_label>Metformin plus pioglitazone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to participate in this present study;&#xD;
&#xD;
          -  Patients with type 2 diabetes receiving stable monotherapy of DPP-IV inhibitors,&#xD;
             SGLT-2 inhibitors or insulin secretagogues for more than 3 months;&#xD;
&#xD;
          -  Screening glycated hemoglobin (HbA1c) between 7.0% and 10.0%;&#xD;
&#xD;
          -  Regular diet and exercise;&#xD;
&#xD;
          -  Body mass index (BMI) â‰¥ 18.5 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intolerance of metformin, pioglitazone and acarbose;&#xD;
&#xD;
          -  Severe liver disease or elevated transaminases (2.5-fold the upper limit);&#xD;
&#xD;
          -  Renal dysfunction or elevated creatinine (1.3-fold the upper limit);&#xD;
&#xD;
          -  Systemic steroids therapy or other medication influencing cholesterol metabolism in&#xD;
             the past 3 months;&#xD;
&#xD;
          -  Infection or stress state in the past 4 weeks;&#xD;
&#xD;
          -  Pregnancy or lactation;&#xD;
&#xD;
          -  Patients otherwise adjudged by the investigator to be inappropriate for inclusion into&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianhua Ma, professor</last_name>
    <phone>18951670116</phone>
    <email>majianhua196503@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanjing First Hospital, Nanjing Medical Univesity</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Ma, Professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 18, 2022</study_first_submitted>
  <study_first_submitted_qc>November 28, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>November 28, 2022</last_update_submitted>
  <last_update_submitted_qc>November 28, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

